Articles From: GENIVI Alliance Honors Wind River with Most Valuable Contributor Award to Genpact to Present at Baird Business Solutions Conference


2013/5/14
Wind River® , a world leader in embedded and mobile software, is a winner of the Most Valuable Contributor (MVC) award in the Company category from the GENIVI® Alliance .
Sign-up for GENIVI Alliance Honors Wind River with Most Valuable Contributor Award investment picks
2013/5/8
GenMark Diagnostics, Inc. (Nasdaq:GNMK) , a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the first quarter ended March 31, 2013.
Sign-up for GenMark Diagnostics Reports First Quarter 2013 Results investment picks
2013/3/12
GenMark Diagnostics, Inc. (Nasdaq:GNMK) , a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the fourth quarter and year ended December 31, 2012.
Sign-up for GenMark Diagnostics Reports Fourth Quarter and Year End 2012 Results investment picks
2013/4/25
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its first quarter earnings results after market close on Wednesday, May 8, 2013.
Sign-up for GenMark Diagnostics Schedules First Quarter 2013 Financial Results Conference Call for May 8, 2013 investment picks
2013/2/28
GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its fourth quarter and full year 2012 earnings results after market close on Tuesday, March 12, 2013.
Sign-up for GenMark Diagnostics Schedules Fourth Quarter and Full Year 2012 Financial Results and Conference Call for March 12, 2013 investment picks
2013/5/10
GenMark Diagnostics, Inc. (NASDAQ: GNMK) , a leading provider of automated, multiplex molecular diagnostic testing systems, will present at the Bank of America Merrill Lynch 2013 Healthcare Conference to be held at Encore at the Wynn in Las Vegas on May 15, 2013.
Sign-up for GenMark Diagnostics to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference investment picks
2013/5/2
Findings Demonstrate Utility of Oncotype DX® to Guide Radiation Treatment Decision for DCIS Patients and Support Expanded Access and Reimbursement REDWOOD CITY, Calif.
Sign-up for Genomic Health and ECOG-ACRIN Cancer Research Group Announce Publication of Positive DCIS Validation Study in the Journal of the National Cancer Institute investment picks
2013/5/8
Groundbreaking Results from University of California, San Francisco (UCSF) Clinical Validation Study Presented at American Urological Association (AUA) Annual Meeting First-of-its-Kind, Biopsy-Based Test Developed and Validated in Seven Studies Including More Than 1,100 Patients SAN DIEGO , May 8, 2013 /PRNewswire/ --  Genomic Health, Inc. (Nasdaq: GHDX) is making its Oncotype DX® prostate cancer test available to physicians and their patients today following the presentation by the University of California, San Francisco (UCSF) of a positive clinical validation study at the 2013 American Urological Association (AUA) Annual Meeting in San Diego.
Sign-up for Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Invasive Treatments investment picks
2013/5/2
Product Revenue Increased 8% Compared to Prior Year Oncotype DX® Prostate Cancer Test to be Available Immediately Following Presentation by UCSF Investigators of their Landmark Clinical Study Results at AUA on Wednesday, May 8 Oncotype DX DCIS Clinical Validation Study Scheduled to Publish Online in Journal of the National Cancer Institute Today 10 Abstracts Accepted for Presentation at ASCO, Highlighting Breast, Colon and Prostate Progress Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces First Quarter 2013 Financial Results and Business Progress investment picks
2013/5/1
Complete Results from UCSF-Led Validation Study to be Presented Earlier that Day at the American Urological Association (AUA) Annual Meeting in San Diego Collaborators from the University of California, San Francisco (UCSF) and the Cleveland Clinic to Join Management Team REDWOOD CITY,Calif., May 1, 2013 /PRNewswire/ --  Genomic Health, Inc.   (Nasdaq: GHDX) today announced that it will host an investor webcast and conference call to discuss the positive development and clinical validation study results of its biopsy-based Oncotype DX prostate cancer test on Wednesday, May 8, 2013 at 1:00 p.m. Pacific Time .
Sign-up for Genomic Health Announces Investor Webcast and Conference Call to Review Positive Clinical Validation and Development of the Oncotype DX® Prostate Cancer Test on Wednesday, May 8, 2013 investment picks
2013/3/13
Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy Oncotype DX DCIS validation study accepted by peer-reviewed journal for publication in coming months REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Large Study of Oncotype DX® to Quantify Risk of Loco-Regional Recurrence in Node-positive Breast Cancer Patients and Acceptance of Oncotype DX DCIS Validation Study for Publication investment picks
2013/4/17
Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Publication of Second Positive Validation of Oncotype DX Colon Cancer Test Confirming Its Value Beyond Conventional Markers investment picks
2013/2/25
Results Presented at the 14th Annual Advances in Genome Biology and Technology Meeting Reveal Novel Method for RNA-Sequencing and Mutation Identification REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology investment picks
2013/2/6
Record 4th Quarter Revenue of $60.4 Million 14% Increase in Full-Year Revenue Positive Prostate Cancer Data Accepted for Oral Presentation at American Urological Association (AUA) Annual Meeting; Oncotype DX® Prostate Cancer Test Launch on Track for Second Quarter 2013 Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook investment picks
2013/3/15
New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients Results Reinforce Oncotype DX as the Only Genomic Test to Guide Chemotherapy Decisions REDWOOD CITY, Calif.
Sign-up for Genomic Health Presents Twenty Two International Studies Demonstrating Worldwide Adoption and Value of Oncotype DX® Breast Cancer Test investment picks
2013/4/3
Complete Results from Positive Clinical Validation Study to be Presented at 2013 American Urological Association (AUA) Annual Meeting Company to Make Oncotype DX Prostate Cancer Test Available to Physicians and Prostate Cancer Patients by End of Second Quarter REDWOOD CITY, Calif.
Sign-up for Genomic Health to Address One of the Most Significant Needs in Men's Health with the Oncotype DX® Prostate Cancer Test investment picks
2013/4/25
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 2, 2013 investment picks
2013/1/30
REDWOOD CITY , Calif., Jan.
Sign-up for Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013 investment picks
2013/5/7
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference investment picks
2013/2/6
Adds Healthcare Payer Industry Domain Expertise Strengthens Capabilities in Addressing New Healthcare Regulations NEW YORK , Feb.
Sign-up for Genpact Acquires Healthcare Business Services Company JAWOOD investment picks
2013/5/15
Companies Recognized for Close Partnership in Achieving Significant Order Management Savings and Increased Customer Satisfaction NEW YORK , May 15, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, Momentive Specialty Chemicals Inc. ("MSC") and Momentive Performance Materials Inc. ("MPM") have received the European Outsourcing Association (EOA) award in the "End User of the Year" category.
Sign-up for Genpact and Momentive Win European Outsourcing Association Award in the "End User of the Year" Category investment picks
2013/5/1
One Year After the Acquisition of Accounting Plaza, Genpact Provides Business Process Management and Technology Services to Growing Number of Dutch Clients NEW YORK and WORMER, Netherlands , May 1, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, has significantly strengthened its services delivery operations in The Netherlands one year after its acquisition of Accounting Plaza.
Sign-up for Genpact Builds Its Dutch Presence investment picks
2013/4/15
Genpact Co-Innovating with Clients Including Symantec to Develop New Industry Solutions to Leverage Big Data NEW YORK , April 15, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, today announced that it has developed and launched its Smart Decision Lab to facilitate collaboration and innovation with clients and industry experts, leveraging the use of data, analytics and technology in conjunction with process expertise.
Sign-up for Genpact Launches Smart Decision Lab for Analytics Services investment picks
2013/4/3
Broadens Genpact's BPaaS Offering to Optimize Mortgage Workflow, Mitigate Compliance Risk, Reduce Total Costs and Improve Cycle Time NEW YORK , April 3, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, announced today that it has released its next generation of applications from its Quantum technology platform for loan origination processing.
Sign-up for Genpact Mortgage Services Releases the Next Generation of the Quantum Loan Origination System investment picks
2013/4/11
NEW YORK , April 11, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, today announced that it has nominated Laura Conigliaro for election to its Board of Directors.
Sign-up for Genpact Nominates Laura Conigliaro to Board of Directors investment picks
2013/5/1
Revenues of $503.8 Million, Up 15.7% Adjusted Income from Operations of $82.8 Million, Up 15.6% Cash Flow from Operations of $31.5 Million NEW YORK , May 1, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, today announced financial results for the first quarter ended March 31, 2013 .
Sign-up for Genpact Reports Results for the First Quarter of 2013 investment picks
2013/4/8
NEW YORK , April 8, 2013 /PRNewswire/ -- Genpact Limited (NYSE: G) , a global leader in business process management and technology services, will announce results for the first quarter ended March 31, 2013 after market close on Wednesday, May 1 .
Sign-up for Genpact Schedules Earnings Announcement and Conference Call for First Quarter 2013 Results investment picks
2013/4/25
Genpact Recognized for Making a Substantial Impact on the Consumer Goods Market with Innovative Business Process Management Services NEW YORK , April 25, 2013 /PRNewswire/ --   Genpact Limited (NYSE: G) , a global leader in business process management and technology services, today announced it has been recognized as a 2013 Editors' Pick in the Annual Consumer Goods Technology (CGT) Readers' Choice Survey.
Sign-up for Genpact Selected as Editors' Pick Provider in Consumer Goods Technology Readers' Choice Survey investment picks
2013/2/25
NEW YORK , Feb.
Sign-up for Genpact to Present at Baird Business Solutions Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: GENIVI Alliance Honors Wind River with Most Valuable Contributor Award to Genpact to Present at Baird Business Solutions Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity